Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.53 |
| ▸ | ATR | Q13535 | 5/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.39 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.39 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673181 | 1.00 | MTOR (0.53) | MTORPIK3CAPIK3CDATRCHEK1 | |
| SCHEMBL1611443 | 1.00 | MTOR (0.53) | MTORPIK3CAPIK3CDATRCHEK1 | |
| SCHEMBL1612230 | 0.85 | MTOR (0.57) | MTORPIK3CAPIK3CDATRCHEK1 | |
| SCHEMBL25235943 | 0.85 | MTOR (0.57) | MTORPIK3CAPIK3CDATRCHEK1 | |
| SCHEMBL25080274 | 0.85 | MTOR (0.50) | MTORPIK3CAPIK3CDATRCHEK1 | |
| SCHEMBL25080284 | 0.85 | MTOR (0.50) | MTORPIK3CAPIK3CDATRCHEK1 | |
| SCHEMBL799324 | 0.85 | MTOR (0.57) | MTORPIK3CAPIK3CDATRCHEK1 | |
| SCHEMBL25292440 | 0.83 | MTOR (0.48) | MTORPIK3CAPIK3CDATRCHEK1 | |
| SCHEMBL25243745 | 0.83 | MTOR (0.48) | MTORPIK3CAPIK3CDATRCHEK1 | |
| SCHEMBL25080608 | 0.83 | MTOR (0.48) | MTORPIK3CAPIK3CDATRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2498780-B1 | N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8288381-B2 | N-9 substituted purine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2498780-A2 | N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110086841-A1 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2010138589-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086841-A1 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ADORA3, ADORA2A, ADORA2B | MTOR 3111/4885PIK3CA 1026/4885PIK3CD 2190/4885 |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | MTOR 177/4885PIK3CA 1/4885PIK3CD 3/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | MTOR 181/4885PIK3CA 1/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.